Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Reddy's submission on April 28, 2026, describing it as the first generic semaglutide authorized by Health Canada and the first to be approved in the G7
This growing mix of preclinical data, clinical observations, and patient anecdotes suggests that SIBO may be a significant, though underrecognised, side effect of GLP1 weight-loss treatments for some people
No tolerance has been demonstrated following repeated administration in research models
These are data from controlled clinical trials and do not constitute a guarantee of effect
US$ 28.17
US$ 27.95
US$ 26.30
.webp)
US$ 28.66
US$ 24.63
